VSP-17, a New PPAR Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin

doi:10.3390/molecules23010121

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物靶标结构与功能中心

	VSP-17, a New PPAR Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin
	Wang, Yuhui 2,3; Zhu, Menglin 2,3; Yuan, Bo 2,3; Zhang, Kefeng 2,3; Zhong, Mingli 2,3; Yi, Wei 1; Xu, Xiaotian 2,3; Duan, Xiaoqun 2,3
刊名	MOLECULES
	2018-01
卷号	23 期号:1
关键词	VSP-17 triple-negative breast cancer metastasis E-cadherin PPAR agonist
ISSN号	1420-3049
DOI	10.3390/molecules23010121
文献子类	Article
英文摘要	Triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer, shows higher metastases and relapse rates than other subtypes. The metastasis of TNBC is the main reason for the death of TNBC patients. Increasing evidence has shown that inhibiting the metastasis of TNBC is a good method for TNBC treatment. Here, VSP-17 was designed and synthesized as an agonist of PPAR, evidenced by upregulating the expression of CD36 and increasing the activity of PPAR reporter gene. VSP-17 obviously inhibited the migration and invasion process of MDA-MB-231 cells but showed little effect on the viability of MDA-MB-231 cells. Notably, VSP-17 could selectively promote the expression of E-cadherin without affecting the expression of BRMS1, CXCL12, MMP9, Orai1, Stim1, TGF-, and VEGF. In addition, VSP-17 significantly suppressed the metastasis of liver and promoted the expression of E-cadherin in MDA-MB-231 xenograft model. In conclusion, VSP-17 inhibited the metastasis process of TNBC via upregulating the expression of E-cadherin.
资助项目	National Natural Science Fund of China[81660604] ; Natural Science Fund of Guangxi[2017GXNSFBA198104] ; special funding for Guangxi BaGui Scholars[00000000] ; special funding for Guangxi basic skills of young teachers in university[00000000]
WOS关键词	TARGETED THERAPIES ; INVASION ; PROGRESSION ; CELLS ; CARCINOGENESIS ; IDENTIFICATION ; PIOGLITAZONE ; TOXICITY ; PATHWAY ; MARKERS
WOS研究方向	Biochemistry & Molecular Biology ; Chemistry
语种	英语
出版者	MDPI
WOS记录号	WOS:000425082500115
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/272332]
专题	药物靶标结构与功能中心
通讯作者	Xu, Xiaotian; Duan, Xiaoqun
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Medica, Shanghai 201203, Peoples R China 2.Guilin Med Univ, Guangxi Coll, 109 Huanchengbei Rd Two, Guilin 541004, Peoples R China; 3.Guilin Med Univ, Univ Key Lab Pharmacol, 109 Huanchengbei Rd Two, Guilin 541004, Peoples R China;
推荐引用方式 GB/T 7714	Wang, Yuhui,Zhu, Menglin,Yuan, Bo,et al. VSP-17, a New PPAR Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin[J]. MOLECULES,2018,23(1).
APA	Wang, Yuhui.,Zhu, Menglin.,Yuan, Bo.,Zhang, Kefeng.,Zhong, Mingli.,...&Duan, Xiaoqun.(2018).VSP-17, a New PPAR Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin.MOLECULES,23(1).
MLA	Wang, Yuhui,et al."VSP-17, a New PPAR Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin".MOLECULES 23.1(2018).